Canada’s Valeant to buy Salix in $10.1 billion deal

NEW YORK (Reuters) – Canada’s Valeant Pharmaceuticals International Inc agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd in an all-cash deal valued at about $10.1 billion, the two companies said on Sunday.

Leave a Reply

Read the original at Reuters: Top News.